fig1

Exploring YAP1-related TIME in SCLC: implications for survival and treatment response to immuno-chemotherapy

Figure 1. The cell proportion and cell density of various immune cells in ES-SCLC. Patients are grouped according to the efficacy of immunotherapy, and the tumor parenchyma and stromal regions are divided based on PanCK staining. (A) The proportion of various immune cells in tissue specimens; (B) The cell density of various immune cells in tissue specimens. ES-SCLC: Extensive-stage small-cell lung cancer.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/